Only a few of the Lilly and Regeneron monoclonal antibodies available for the treatment of Covid-19 are being used each week, said Dr. John Redd, chief medical officer in the US Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response.
"The highest weekly utilization by state has been 21%," Redd said in a Q&A during a webinar on Wednesday hosted by the National Academies of Sciences, Engineering and Medicine.
"We’ll be getting updated numbers this week," Redd said, adding that uptake in the use of monoclonal antibodies is encouraged and efforts are being made to share information about these treatments, possibly in new locations — such as nursing homes — where they may be valuable.